How the Experts Manage Tardive Dyskinesia

Not long ago the expert consensus on tardive dyskinesia (TD) was that-aside from stopping the antipsychotic-it was not treatable.¹ That has changed since the release of the new VMAT2 inhibitors: deutetrabenazine (Austedo) and valbenazine (Ingrezza) in 2017. Guidelines are being updated to incorporate these advances, and a recent Delphi consensus statement is a step in that direction. The group surveyed 29 physicians with expertise in TD: 23 psychiatrists and 6 neurologists. Here is what they have agreed on so far.²